{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T19:32:17Z","timestamp":1791055937737,"version":"4.1.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2011,3,17]],"date-time":"2011-03-17T00:00:00Z","timestamp":1300320000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1186\/1756-9966-30-30","type":"journal-article","created":{"date-parts":[[2011,3,17]],"date-time":"2011-03-17T15:38:46Z","timestamp":1300376326000},"source":"Crossref","is-referenced-by-count":64,"title":["Comparison of KRAS and EGFR gene status between primary non-small cell lung cancer and local lymph node metastases: implications for clinical practice"],"prefix":"10.1186","volume":"30","author":[{"given":"Leina","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huanling","family":"Luan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongli","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changli","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baocun","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,3,17]]},"reference":[{"key":"450_CR1","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/S0025-6196(11)60735-0","volume":"83","author":"JR Molina","year":"2008","unstructured":"Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA: Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 2008, 83: 584-594. 10.4065\/83.5.584.","journal-title":"Mayo Clin Proc"},{"key":"450_CR2","doi-asserted-by":"publisher","first-page":"225","DOI":"10.3322\/caac.20006","volume":"59","author":"A Jemal","year":"2009","unstructured":"Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ: Cancer statistics, 2009. CA Cancer J Clin. 2009, 59: 225-249. 10.3322\/caac.20006.","journal-title":"CA Cancer J Clin"},{"key":"450_CR3","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1136\/bmj.325.7362.452","volume":"325","author":"HH Hansen","year":"2002","unstructured":"Hansen HH: Treatment of advanced non-small cell lung cancer. BMJ. 2002, 325: 452-453. 10.1136\/bmj.325.7362.452.","journal-title":"BMJ"},{"key":"450_CR4","doi-asserted-by":"publisher","first-page":"3798","DOI":"10.1200\/JCO.2003.11.069","volume":"21","author":"FR Hirsch","year":"2003","unstructured":"Hirsch FR, Varella-Garcia M, Bunn PA, Di Maria MV, Veve R, Bremmes RM, Baron AE, Zeng C, Franklin WA: Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol. 2003, 21: 3798-3807. 10.1200\/JCO.2003.11.069.","journal-title":"J Clin Oncol"},{"key":"450_CR5","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1126\/science.1099314","volume":"304","author":"JG Paez","year":"2004","unstructured":"Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, et al.: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004, 304: 1497-1500. 10.1126\/science.1099314.","journal-title":"Science"},{"key":"450_CR6","doi-asserted-by":"publisher","first-page":"13306","DOI":"10.1073\/pnas.0405220101","volume":"101","author":"W Pao","year":"2004","unstructured":"Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, Singh B, Heelan R, Rusch V, Fulton L, et al.: EGF receptor gene mutations are common in lung cancers from \"never smokers\" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA. 2004, 101: 13306-13311. 10.1073\/pnas.0405220101.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"Suppl 3","key":"450_CR7","doi-asserted-by":"publisher","first-page":"S109","DOI":"10.3816\/CLC.2008.s.016","volume":"9","author":"R Pirker","year":"2008","unstructured":"Pirker R, Minar W, Filipits M: Integrating epidermal growth factor receptor-targeted therapies into platinum-based chemotherapy regimens for newly diagnosed non-small-cell lung cancer. Clin Lung Cancer. 2008, 9 (Suppl 3): S109-115. 10.3816\/CLC.2008.s.016.","journal-title":"Clin Lung Cancer"},{"key":"450_CR8","doi-asserted-by":"publisher","first-page":"188","DOI":"10.2174\/138161209787002915","volume":"15","author":"R Pirker","year":"2009","unstructured":"Pirker R, Filipits M: Targeted therapies in lung cancer. Curr Pharm Des. 2009, 15: 188-206. 10.2174\/138161209787002915.","journal-title":"Curr Pharm Des"},{"key":"450_CR9","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1056\/NEJMoa040938","volume":"350","author":"TJ Lynch","year":"2004","unstructured":"Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, et al.: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004, 350: 2129-2139. 10.1056\/NEJMoa040938.","journal-title":"N Engl J Med"},{"key":"450_CR10","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1200\/JCO.2003.10.038","volume":"21","author":"M Fukuoka","year":"2003","unstructured":"Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, Nishiwaki Y, Vansteenkiste J, Kudoh S, Rischin D, et al.: Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol. 2003, 21: 2237-2246. 10.1200\/JCO.2003.10.038.","journal-title":"J Clin Oncol"},{"key":"450_CR11","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1001\/jama.290.16.2149","volume":"290","author":"MG Kris","year":"2003","unstructured":"Kris MG, Natale RB, Herbst RS, Lynch TJ, Prager D, Belani CP, Schiller JH, Kelly K, Spiridonidis H, Sandler A, et al.: Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. Jama. 2003, 290: 2149-2158. 10.1001\/jama.290.16.2149.","journal-title":"Jama"},{"key":"450_CR12","doi-asserted-by":"publisher","first-page":"5900","DOI":"10.1200\/JCO.2005.02.857","volume":"23","author":"DA Eberhard","year":"2005","unstructured":"Eberhard DA, Johnson BE, Amler LC, Goddard AD, Heldens SL, Herbst RS, Ince WL, Janne PA, Januario T, Johnson DH, et al.: Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol. 2005, 23: 5900-5909. 10.1200\/JCO.2005.02.857.","journal-title":"J Clin Oncol"},{"key":"450_CR13","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1038\/sj.cr.7290289","volume":"15","author":"BM Qin","year":"2005","unstructured":"Qin BM, Chen X, Zhu JD, Pei DQ: Identification of EGFR kinase domain mutations among lung cancer patients in China: implication for targeted cancer therapy. Cell Res. 2005, 15: 212-217. 10.1038\/sj.cr.7290289.","journal-title":"Cell Res"},{"key":"450_CR14","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1093\/annonc\/mdi340","volume":"16","author":"XT Zhang","year":"2005","unstructured":"Zhang XT, Li LY, Mu XL, Cui QC, Chang XY, Song W, Wang SL, Wang MZ, Zhong W, Zhang L: The EGFR mutation and its correlation with response of gefitinib in previously treated Chinese patients with advanced non-small-cell lung cancer. Ann Oncol. 2005, 16: 1334-1342. 10.1093\/annonc\/mdi340.","journal-title":"Ann Oncol"},{"key":"450_CR15","doi-asserted-by":"publisher","first-page":"2890","DOI":"10.1158\/1078-0432.CCR-06-3043","volume":"13","author":"E Massarelli","year":"2007","unstructured":"Massarelli E, Varella-Garcia M, Tang X, Xavier AC, Ozburn NC, Liu DD, Bekele BN, Herbst RS, Wistuba II: KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin Cancer Res. 2007, 13: 2890-2896. 10.1158\/1078-0432.CCR-06-3043.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"450_CR16","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/S0169-5002(99)00129-4","volume":"28","author":"MC Perry","year":"2000","unstructured":"Perry MC, Ihde DC, Herndon JE, Grossbard ML, Grethein SJ, Atkins JN, Vokes EE, Green MR: Paclitaxel\/ifosfamide or navelbine\/ifosfamide chemotherapy for advanced non-small cell lung cancer: CALGB 9532. Lung cancer. 2000, 28 (1): 63-68. 10.1016\/S0169-5002(99)00129-4.","journal-title":"Lung cancer"},{"key":"450_CR17","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1378\/chest.128.1.452","volume":"128","author":"P Yang","year":"2005","unstructured":"Yang P, Allen MS, Aubry MC, Wampfler JA, Marks RS, Edell ES, Thibodeau S, Adjei AA, Jett J, Deschamps C: Clinical features of 5,628 primary lung cancer patients: experience at Mayo Clinic from 1997 to 2003. Chest. 2005, 128: 452-462. 10.1378\/chest.128.1.452.","journal-title":"Chest"},{"key":"450_CR18","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1054\/bjoc.1999.0878","volume":"82","author":"S Petersen","year":"2000","unstructured":"Petersen S, Aninat-Meyer M, Schluns K, Gellert K, Dietel M, Petersen I: Chromosomal alterations in the clonal evolution to the metastatic stage of squamous cell carcinomas of the lung. Br J Cancer. 2000, 82: 65-73. 10.1054\/bjoc.1999.0878.","journal-title":"Br J Cancer"},{"key":"450_CR19","first-page":"83","volume":"8","author":"T Ubagai","year":"2001","unstructured":"Ubagai T, Matsuura S, Tauchi H, Itou K, Komatsu K: Comparative genomic hybridization analysis suggests a gain of chromosome 7p associated with lymph node metastases in non-small cell lung cancer. Oncol Rep. 2001, 8: 83-88.","journal-title":"Oncol Rep"},{"key":"450_CR20","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1111\/j.1349-7006.2008.00782.x","volume":"99","author":"K Taniguchi","year":"2008","unstructured":"Taniguchi K, Okami J, Kodama K, Higashiyama M, Kato K: Intratumor heterogeneity of epidermal growth factor receptor mutations in lung cancer and its correlation to the response to gefitinib. Cancer Sci. 2008, 99: 929-935. 10.1111\/j.1349-7006.2008.00782.x.","journal-title":"Cancer Sci"},{"key":"450_CR21","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.humpath.2009.06.019","volume":"41","author":"SE Monaco","year":"2010","unstructured":"Monaco SE, Nikiforova MN, Cieply K, Teot LA, Khalbuss WE, Dacic S: A comparison of EGFR and KRAS status in primary lung carcinoma and matched metastases. Hum Pathol. 2010, 41: 94-102. 10.1016\/j.humpath.2009.06.019.","journal-title":"Hum Pathol"},{"key":"450_CR22","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1093\/annonc\/mdl038","volume":"17","author":"A Italiano","year":"2006","unstructured":"Italiano A, Vandenbos FB, Otto J, Mouroux J, Fontaine D, Marcy PY, Cardot N, Thyss A, Pedeutour F: Comparison of the epidermal growth factor receptor gene and protein in primary non-small-cell-lung cancer and metastatic sites: implications for treatment with EGFR-inhibitors. Ann Oncol. 2006, 17: 981-985. 10.1093\/annonc\/mdl038.","journal-title":"Ann Oncol"},{"key":"450_CR23","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1097\/JTO.0b013e31815e8ba2","volume":"3","author":"C Bozzetti","year":"2008","unstructured":"Bozzetti C, Tiseo M, Lagrasta C, Nizzoli R, Guazzi A, Leonardi F, Gasparro D, Spiritelli E, Rusca M, Carbognani P, et al.: Comparison between epidermal growth factor receptor (EGFR) gene expression in primary non-small cell lung cancer (NSCLC) and in fine-needle aspirates from distant metastatic sites. J Thorac Oncol. 2008, 3: 18-22. 10.1097\/JTO.0b013e31815e8ba2.","journal-title":"J Thorac Oncol"},{"key":"450_CR24","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1038\/sj.bjc.6604629","volume":"99","author":"A Kalikaki","year":"2008","unstructured":"Kalikaki A, Koutsopoulos A, Trypaki M, Souglakos J, Stathopoulos E, Georgoulias V, Mavroudis D, Voutsina A: Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC. Br J Cancer. 2008, 99: 923-929. 10.1038\/sj.bjc.6604629.","journal-title":"Br J Cancer"},{"key":"450_CR25","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1097\/JTO.0b013e3181a94af4","volume":"4","author":"S Park","year":"2009","unstructured":"Park S, Holmes-Tisch AJ, Cho EY, Shim YM, Kim J, Kim HS, Lee J, Park YH, Ahn JS, Park K, et al.: Discordance of molecular biomarkers associated with epidermal growth factor receptor pathway between primary tumors and lymph node metastases in non-small cell lung cancer. J Thorac Oncol. 2009, 4: 809-815. 10.1097\/JTO.0b013e3181a94af4.","journal-title":"J Thorac Oncol"},{"key":"450_CR26","doi-asserted-by":"publisher","first-page":"4554","DOI":"10.1158\/1078-0432.CCR-09-0089","volume":"15","author":"K Schmid","year":"2009","unstructured":"Schmid K, Oehl N, Wrba F, Pirker R, Pirker C, Filipits M: EGFR\/KRAS\/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases. Clin Cancer Res. 2009, 15: 4554-4560. 10.1158\/1078-0432.CCR-09-0089.","journal-title":"Clin Cancer Res"},{"key":"450_CR27","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al.: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009, 45: 228-247. 10.1016\/j.ejca.2008.10.026.","journal-title":"Eur J Cancer"},{"key":"450_CR28","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1038\/418823a","volume":"418","author":"R Bernards","year":"2002","unstructured":"Bernards R, Weinberg RA: A progression puzzle. Nature. 2002, 418: 823-10.1038\/418823a.","journal-title":"Nature"},{"key":"450_CR29","doi-asserted-by":"publisher","first-page":"2682","DOI":"10.1002\/cncr.25014","volume":"116","author":"AB Cortot","year":"2010","unstructured":"Cortot AB, Italiano A, Burel-Vandenbos F, Martel-Planche G, Hainaut P: KRAS mutation status in primary nonsmall cell lung cancer and matched metastases. Cancer. 2010, 116: 2682-2687. 10.1002\/cncr.25014.","journal-title":"Cancer"},{"key":"450_CR30","first-page":"889","volume":"8","author":"N Noda","year":"2001","unstructured":"Noda N, Matsuzoe D, Konno T, Kawahara K, Yamashita Y, Shirakusa T: K-ras gene mutations in non-small cell lung cancer in Japanese. Oncol Rep. 2001, 8: 889-892.","journal-title":"Oncol Rep"},{"key":"450_CR31","doi-asserted-by":"publisher","first-page":"8919","DOI":"10.1158\/0008-5472.CAN-04-2818","volume":"64","author":"T Kosaka","year":"2004","unstructured":"Kosaka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T, Mitsudomi T: Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res. 2004, 64: 8919-8923. 10.1158\/0008-5472.CAN-04-2818.","journal-title":"Cancer Res"},{"key":"450_CR32","doi-asserted-by":"publisher","first-page":"e17","DOI":"10.1371\/journal.pmed.0020017","volume":"2","author":"W Pao","year":"2005","unstructured":"Pao W, Wang TY, Riely GJ, Miller VA, Pan Q, Ladanyi M, Zakowski MF, Heelan RT, Kris MG, Varmus HE: KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med. 2005, 2: e17-10.1371\/journal.pmed.0020017.","journal-title":"PLoS Med"},{"key":"450_CR33","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1016\/j.humpath.2005.08.007","volume":"36","author":"M Suzuki","year":"2005","unstructured":"Suzuki M, Shigematsu H, Hiroshima K, Iizasa T, Nakatani Y, Minna JD, Gazdar AF, Fujisawa T: Epidermal growth factor receptor expression status in lung cancer correlates with its mutation. Hum Pathol. 2005, 36: 1127-1134. 10.1016\/j.humpath.2005.08.007.","journal-title":"Hum Pathol"},{"key":"450_CR34","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1158\/1078-0432.CCR-05-1981","volume":"12","author":"IY Tam","year":"2006","unstructured":"Tam IY, Chung LP, Suen WS, Wang E, Wong MC, Ho KK, Lam WK, Chiu SW, Girard L, Minna JD, et al.: Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features. Clin Cancer Res. 2006, 12: 1647-1653. 10.1158\/1078-0432.CCR-05-1981.","journal-title":"Clin Cancer Res"},{"key":"450_CR35","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.cancergencyto.2006.10.007","volume":"173","author":"NC Bae","year":"2007","unstructured":"Bae NC, Chae MH, Lee MH, Kim KM, Lee EB, Kim CH, Park TI, Han SB, Jheon S, Jung TH, Park JY: EGFR, ERBB2, and KRAS mutations in Korean non-small cell lung cancer patients. Cancer Genet Cytogenet. 2007, 173: 107-113. 10.1016\/j.cancergencyto.2006.10.007.","journal-title":"Cancer Genet Cytogenet"},{"key":"450_CR36","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1097\/JTO.0b013e318160c607","volume":"3","author":"JL Marks","year":"2008","unstructured":"Marks JL, Broderick S, Zhou Q, Chitale D, Li AR, Zakowski MF, Kris MG, Rusch VW, Azzoli CG, Seshan VE, et al.: Prognostic and therapeutic implications of EGFR and KRAS mutations in resected lung adenocarcinoma. J Thorac Oncol. 2008, 3: 111-116. 10.1097\/JTO.0b013e318160c607.","journal-title":"J Thorac Oncol"},{"key":"450_CR37","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.1002\/cncr.23925","volume":"113","author":"CC Wu","year":"2008","unstructured":"Wu CC, Hsu HY, Liu HP, Chang JW, Chen YT, Hsieh WY, Hsieh JJ, Hsieh MS, Chen YR, Huang SF: Reversed mutation rates of KRAS and EGFR genes in adenocarcinoma of the lung in Taiwan and their implications. Cancer. 2008, 113: 3199-3208. 10.1002\/cncr.23925.","journal-title":"Cancer"}],"container-title":["Journal of Experimental & Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1756-9966-30-30.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1756-9966-30-30\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1756-9966-30-30.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,1,23]],"date-time":"2019-01-23T03:23:53Z","timestamp":1548213833000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/1756-9966-30-30"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3,17]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["450"],"URL":"https:\/\/doi.org\/10.1186\/1756-9966-30-30","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,3,17]]},"article-number":"30"}}